Preclinical Model To Test Human Papillomavirus Virus (HPV) Capsid Vaccines In Vivo Using Infectious HPV/Cottontail Rabbit Papillomavirus Chimeric Papillomavirus Particles
- 15 December 2006
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (24) , 12393-12397
- https://doi.org/10.1128/jvi.01583-06
Abstract
A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) was recently approved for human use. It is generally assumed that VLP vaccines protect by inducing type-specific neutralizing antibodies. Preclinical animal models cannot be used to test for protection against HPV infections due to species restriction. We developed a model using chimeric HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of HPV VLP vaccines in rabbits. Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challenged with both homologous (CRPV capsid) and chimeric (HPV-16 capsid) particles. Strong type-specific protection was observed, demonstrating the potential application of this approach.Keywords
This publication has 20 references indexed in Scilit:
- Papillomavirus Particles Assembled in 293TT Cells Are Infectious In VivoJournal of Virology, 2006
- Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiationProceedings of the National Academy of Sciences, 2005
- Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2Published by Elsevier ,2005
- Against which human papillomavirus types shall we vaccinate and screen? the international perspectiveInternational Journal of Cancer, 2004
- Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18Virology, 2004
- Efficient Intracellular Assembly of Papillomaviral VectorsJournal of Virology, 2004
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- Minor Capsid Protein of Human Genital Papillomaviruses Contains Subdominant, Cross-Neutralizing EpitopesVirology, 2000
- Virus-like Particles of Bovine Papillomavirus Type 4 in Prophylactic and Therapeutic ImmunizationVirology, 1996
- Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.Proceedings of the National Academy of Sciences, 1995